Open AccessErratum: Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Author(s) -
L. A. Gallo,
] Ward,
A. Fotheringham,
Aowen Zhuang,
DJ Borg,
NB Flemming,
BM Harvie,
TL Kinneally,
S-M Yeh,
D. D. McCarthy,
Hermann Koepsell,
Vallon,
Carol Pollock,
Usha Panchapakesan,
Forbes Jm
Publication year - 2016
Publication title -
scientific reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.24
H-Index - 213
ISSN - 2045-2322
DOI - 10.1038/srep28124
Subject(s) - empagliflozin , albuminuria , medicine , diabetes mellitus , medical research , family medicine , urology , type 2 diabetes , political science , endocrinology , pathology